A healthy investment in healthier futures.

Cryo-Cell has been a publicly traded company since 1991. Governed by the Securities & Exchange Commission, our common stock trades under the OTC QB: symbol CCEL. We specialize in stem cell preservation for family use.

Cryo-Cell Reports Second Quarter 2014 Results

OLDSMAR, Fla., July 7, 2014 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the second fiscal quarter ended May 31, 2014.

"We believe that the growth in the Company's processing and storage fees as well as the growth in net income second quarter fiscal 2014 versus second quarter fiscal 2013 demonstrate that the Company is headed in the right direction," stated David Portnoy, Cryo-Cell's Chairman and Co-CEO. Mr. Portnoy continued, "We will continue to invest the Company's capital resources in those areas which we believe will generate the highest returns for our shareholders."

Mark Portnoy, Cryo-Cell's Co-CEO, added, "Cryo-Cell continues to lead the way in the industry by raising our quality standards and becoming the first private-only cord blood bank in the U.S. to achieve FACT accreditation – the most stringent quality accrediting organization in the field of cellular therapies."



Read More

Cryo-Cell Reports Financial Results for Fiscal 2013

OLDSMAR, Fla., March 3, 2014 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for its fiscal year 2013.

"We believe Cryo-Cell's 2013 financial results give only a hint of the Company's improvements that have been implemented throughout the organization," stated David Portnoy, Cryo-Cell's Chairman and Co-CEO. "We look forward to fiscal year 2014 with much anticipation and believe that Cryo-Cell is very well positioned to benefit financially from its strong position in the cord blood banking industry."

Mark Portnoy, Cryo-Cell's Co-CEO, added, "We believe the increase in revenue in 2013 demonstrates traction for the new direction of the Company. In fact, the positive cash flow from operations was $822,000 in fiscal 2013. Excluding the $1.6 million cash payment related to the termination of the Company's former CEO, cash flow from operations would have been $2.4 million. We hope to see more progress during 2014."



Read More

Cryo-Cell Reports Third Quarter 2013 Results

OLDSMAR, Fla. – October 15, 2013 – Cryo-Cell International, Inc. (the “Company”) (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the fiscal third quarter ended August 31, 2013.

David Portnoy, Cryo-Cell’s Chairman and Co-Chief Executive Officer commented, “Cryo-Cell’s fiscal third quarter 2013 results continue to show that the Company is becoming increasingly more profitable and more successful within the cord blood industry as customers choose Cryo-Cell for its superior quality and top notch service. I know Cryo-Cell has even greater potential that we will strive to realize in the coming years.”

Mark Portnoy, Cryo-Cell’s Co-Chief Executive Officer, added, “The Company’s sales and marketing initiatives have put Cryo-Cell on sounder footing, and we continue to raise the quality of our service in meaningful ways. We believe our qualitative efforts will differentiate us and have a positive impact in the future.”



Read More

Request Investor Information

Send me press release announcements by email: